The process for approving biosimilars has been moving slowly, but Aimee Tharaldson, PharmD, senior clinical consultant of emerging therapies at Express Scripts, foresees them as having the potential to lower costs for the industry and hopes the approval process will pick up speed.
The process for approving biosimilars has been moving slowly, but Aimee Tharaldson, PharmD, senior clinical consultant of emerging therapies at Express Scripts, foresees them as having the potential to lower costs for the industry and hopes the approval process will pick up speed.
Transcript (slightly modified)
A second biosimilar has been approved in the US: how has the process of getting biosimilars approved been going?
I think the process for getting biosimilars to market has been slower than I expected. The 351(k) pathway was established in 2010 as part of the Affordable Care Act. FDA has been releasing draft guidance documents over the past 5 to 6 years, and the first biosimilar was approved 5 years after the pathway was established. Now we just had the second biosimilar approved this year, but we don’t know when that will be launched.
So I think, initially, it’s just been taking a lot of time as there are so many different stakeholders with conflicting interests, as well as the litigation is just going to be a major hurdle to getting these products to market. So it’s been a little bit slow, but I think that it will speed up in the future.
Do you think biosimilars will have a significant impact on lowering cost?
I think initially these biosimilars will be treated more like competing brands just because there aren’t going to be a lot. Pricing at this point seems like they may be about 15% less than the reference biologics so that’s not a huge discount. I do think that over time, once we have more competitors in the market, more biosimilars—hopefully interchangeable biosimilars—that that will really have a significant impact on lowering costs.
When you look at cost of specialty medications—Enbrel and Humira are huge medications and with biosimilar competition coming, I mean, they definitely have the potential to lower costs for the industry.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More